The changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.

ABSTRACT: Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We collected serial passages of cetuximab resistance HNSCC cell lines to perform LC-MS/MS. We identified the IFN pathway as the key target to cause this effect.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Po-Hsien Chiu  

LAB HEAD: Muh-Hwa Yang

PROVIDER: PXD054113 | Pride | 2025-12-29

REPOSITORIES: Pride